Search results
Results from the WOW.Com Content Network
Cancer specific T-cells can be obtained by fragmentation and isolation of tumor infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).
Fig. 1. Processing of tumor antigens recognized by CD8 + T cells. T lymphocytes are cells of the immune system that attack and destroy virus-infected cells, tumor cells and cells from transplanted organs. This occurs because each T cell is endowed with a highly specific receptor that can bind to an antigen present at the
CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells.CTLA-4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells.
Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen-presenting cells (APCs) in the mammalian immune system. [15] In cancer treatment, they aid cancer antigen targeting ...
The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) [27] [28] [29] or genetically re-directed peripheral blood mononuclear cells [30] [31] has been used experimentally to treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies ...
A portion of the recipient's tumor tissue is removed during a surgical procedure prior to treatment. [3] The recipient's T cells (the tumor-infiltrating lymphocytes) are separated from the tumor tissue, multiplied and then infused into the patient in a single dose. [3] T cells are a type of cell that helps the immune system fight cancer and ...
Some cancers that form tumors, such as breast cancer, produce CCL17 which draws T regulatory cells into the area, enhancing the cancer’s ability to invade. [6] On the other hand, CCL17 will also activate tumor-infiltrating lymphocytes tumors. [ 6 ]
Tumor counterattack: Tumors may over-express Fas ligand and induce the apoptosis of infiltrating lymphocytes, allowing the tumor to escape the effects of an immune response. [15] The up-regulation of Fas ligand often occurs following chemotherapy , from which the tumor cells have attained apoptosis resistance.